The reliable supply of molybdenum-99 (99Mo) and its decay product, technetium-99m (99mTc), is a vital component of modern medical diagnostic practices. At present, most of the global production of 99Mo is from highly enriched uranium (HEU) targets. However, all major 99Mo-producing countries have recently agreed to convernt to using low-enriched uranium targetts for the production of 99Mo. This report describes the market impact of this conversion both in terms of costs, available capacity as well as the policy actions that are needed.